

Trust Headquarters
 Russell's Hall Hospital
 Dudley
 West Midlands
 DY1 2HQ

Ref: FOI-112024-0001248

Date: 19/11/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy
- Osimertinib

Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- Lonsurf (Trifluridine - tipiracil)
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only
- Zolbetuximab (Vyloy)

Response

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

Atezolizumab (Tecentriq)	< 5
Durvalumab (Imfinzi)	0
Nivolumab (Opdivo)	< 5
Pembrolizumab (Keytruda)	16
Chemotherapy	76

Radiotherapy	Not recorded in cEPMA system
Chemotherapy AND Radiotherapy	Not recorded in cEPMA system
Osimertinib	12

Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

CAPOX (Capecitabine with Oxaliplatin)	46
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)	< 5
Lonsurf (Trifluridine - tipiracil)	< 5
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	10
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Any other systemic anti-cancer therapy	149
Palliative care only	Not recorded in cEPMA system
Zolbetuximab (Vyloy)	0

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust